免疫治疗药物-话题@MedSci

#免疫治疗药物#

20篇内容 | 1135人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1984548, encodeId=81ed19845481e, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, objectTitle=肺癌，靶向及免疫治疗药物汇总表（2022年6月）, objectType=article, longId=728941, objectId=994de28941cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=994de28941cc, replyNumber=0, likeNumber=87, createdTime=2022-09-06, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=994de28941cc, moduleTitle=肺癌，靶向及免疫治疗药物汇总表（2022年6月）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=994de28941cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984546, encodeId=7004198454621, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, objectTitle=Aimmune Therapeutics在EAACI PAAM数字会议上呈报长期每日口服免疫治疗药物PALFORZIA®（花生过敏原粉剂-dnfp）的免疫学结果新数据, objectType=article, longId=220575, objectId=ad652205e545, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad652205e545, replyNumber=0, likeNumber=0, createdTime=2022-09-20, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad652205e545, moduleTitle=Aimmune Therapeutics在EAACI PAAM数字会议上呈报长期每日口服免疫治疗药物PALFORZIA®（花生过敏原粉剂-dnfp）的免疫学结果新数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad652205e545)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984547, encodeId=2956198454ea1, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, objectTitle=肺癌，靶向及免疫治疗药物汇总表(2022年1月), objectType=article, longId=293345, objectId=2a592933457e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a592933457e, replyNumber=0, likeNumber=86, createdTime=2022-04-26, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a592933457e, moduleTitle=肺癌，靶向及免疫治疗药物汇总表(2022年1月), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a592933457e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984543, encodeId=49c919845437a, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, objectTitle=PD-1免疫治疗药物拓益®尿路上皮癌适应症在中国获批, objectType=article, longId=209983, objectId=86f62099835f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86f62099835f, replyNumber=0, likeNumber=101, createdTime=2021-11-30, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86f62099835f, moduleTitle=PD-1免疫治疗药物拓益®尿路上皮癌适应症在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86f62099835f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984545, encodeId=861619845456f, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, objectTitle=Personalis, Inc.新发表的数据显示，新型复合生物标志物NEOPS™可用于预测晚期黑色素瘤患者对癌症免疫治疗药物的应答, objectType=article, longId=215238, objectId=cb2d215238b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb2d215238b4, replyNumber=0, likeNumber=99, createdTime=2022-06-22, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb2d215238b4, moduleTitle=Personalis, Inc.新发表的数据显示，新型复合生物标志物NEOPS™可用于预测晚期黑色素瘤患者对癌症免疫治疗药物的应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb2d215238b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984544, encodeId=9fc6198454451, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, objectTitle=国内结直肠癌一线免疫治疗药物获批，国内PD-1竞争加剧, objectType=article, longId=212815, objectId=76fd21281501, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76fd21281501, replyNumber=0, likeNumber=98, createdTime=2022-01-20, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76fd21281501, moduleTitle=国内结直肠癌一线免疫治疗药物获批，国内PD-1竞争加剧, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76fd21281501)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984541, encodeId=f4fd1984541ae, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, objectTitle=五类新型肿瘤免疫治疗药物，加强版PD-1药物即将到来, objectType=article, longId=204274, objectId=06f22042e4c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06f22042e4c0, replyNumber=0, likeNumber=83, createdTime=2021-03-31, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06f22042e4c0, moduleTitle=五类新型肿瘤免疫治疗药物，加强版PD-1药物即将到来, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06f22042e4c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984542, encodeId=a1ba198454237, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, objectTitle=过敏性疾病取得里程碑进展，全球蒿属花粉舌下免疫治疗药物上市, objectType=article, longId=209364, objectId=17682093649c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17682093649c, replyNumber=0, likeNumber=93, createdTime=2022-03-11, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17682093649c, moduleTitle=过敏性疾病取得里程碑进展，全球蒿属花粉舌下免疫治疗药物上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17682093649c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984540, encodeId=f8651984540c7, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, objectTitle=CSCO 2020丨CDE高级审评员夏琳：肿瘤免疫治疗药物的临床研发和审评考虑, objectType=article, longId=201052, objectId=27f8201052b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27f8201052b6, replyNumber=0, likeNumber=67, createdTime=2021-04-11, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27f8201052b6, moduleTitle=CSCO 2020丨CDE高级审评员夏琳：肿瘤免疫治疗药物的临床研发和审评考虑, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27f8201052b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984539, encodeId=63831984539b6, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, objectTitle=中国胃癌免疫治疗药物欧狄沃®获批，生存期显著延长, objectType=article, longId=189951, objectId=cadc189951ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cadc189951ee, replyNumber=0, likeNumber=79, createdTime=2021-02-11, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cadc189951ee, moduleTitle=中国胃癌免疫治疗药物欧狄沃®获批，生存期显著延长, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cadc189951ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984538, encodeId=1092198453833, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, objectTitle=针对广泛期小细胞肺癌，免疫治疗药物Imfinzi显著改善生存获益和持久疗效, objectType=article, longId=179249, objectId=c3431e924935, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3431e924935, replyNumber=0, likeNumber=0, createdTime=2020-07-01, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3431e924935, moduleTitle=针对广泛期小细胞肺癌，免疫治疗药物Imfinzi显著改善生存获益和持久疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3431e924935)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984537, encodeId=42b6198453eba, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, objectTitle=2018年值得关注的肿瘤免疫治疗药物, objectType=article, longId=125579, objectId=968d1255e9cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=968d1255e9cf, replyNumber=0, likeNumber=83, createdTime=2018-08-26, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=968d1255e9cf, moduleTitle=2018年值得关注的肿瘤免疫治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=968d1255e9cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984535, encodeId=a637198453580, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, objectTitle=ANN ONCOL:肿瘤类型和免疫治疗药物类别的不同对免疫治疗不良事件的发生差异如何？, objectType=article, longId=108712, objectId=caf6108e122c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=caf6108e122c, replyNumber=0, likeNumber=70, createdTime=2018-06-17, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=caf6108e122c, moduleTitle=ANN ONCOL:肿瘤类型和免疫治疗药物类别的不同对免疫治疗不良事件的发生差异如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=caf6108e122c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984536, encodeId=4f1f1984536fe, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, objectTitle=PNAS:KWAR23抗体——肿瘤免疫治疗药物的有力助手, objectType=article, longId=121202, objectId=08bd12120296, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08bd12120296, replyNumber=0, likeNumber=77, createdTime=2018-09-25, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08bd12120296, moduleTitle=PNAS:KWAR23抗体——肿瘤免疫治疗药物的有力助手, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08bd12120296)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984534, encodeId=5f56198453471, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, objectTitle=Lancet Oncol：PD-1免疫治疗药物能有效治疗恶性胸膜间皮瘤 (KEYNOTE-028), objectType=article, longId=94466, objectId=d9bf94466c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9bf94466c1, replyNumber=0, likeNumber=90, createdTime=2017-11-13, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9bf94466c1, moduleTitle=Lancet Oncol：PD-1免疫治疗药物能有效治疗恶性胸膜间皮瘤 (KEYNOTE-028), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9bf94466c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984533, encodeId=14091984533db, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, objectTitle=强大的肠道菌群！竟然影响黑色素瘤病人对免疫治疗药物的应答, objectType=article, longId=82029, objectId=c0c482029ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0c482029ee, replyNumber=0, likeNumber=77, createdTime=2017-08-22, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0c482029ee, moduleTitle=强大的肠道菌群！竟然影响黑色素瘤病人对免疫治疗药物的应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0c482029ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984532, encodeId=bc891984532fe, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, objectTitle=PD-L1免疫治疗药物avelumab牵手表观药物entinostat，联合治疗卵巢癌研究启动, objectType=article, longId=61803, objectId=98bd618032f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98bd618032f, replyNumber=0, likeNumber=103, createdTime=2016-04-27, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98bd618032f, moduleTitle=PD-L1免疫治疗药物avelumab牵手表观药物entinostat，联合治疗卵巢癌研究启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98bd618032f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984531, encodeId=95fc198453197, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, objectTitle=BMS、默沙东及罗氏免疫治疗药物将成为ASCO会议的焦点, objectType=article, longId=35150, objectId=e77d351500c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e77d351500c, replyNumber=0, likeNumber=90, createdTime=2014-09-24, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e77d351500c, moduleTitle=BMS、默沙东及罗氏免疫治疗药物将成为ASCO会议的焦点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e77d351500c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984530, encodeId=f41519845301a, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, objectTitle=2013年回顾：癌症免疫治疗药物加速崛起, objectType=article, longId=28951, objectId=b6052895168, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6052895168, replyNumber=0, likeNumber=70, createdTime=2014-06-28, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6052895168, moduleTitle=2013年回顾：癌症免疫治疗药物加速崛起, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6052895168)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1984529, encodeId=9b9d1984529f5, content=<a href='/topic/show?id=fc9a290e1cb' target=_blank style='color:#2F92EE;'>#免疫治疗药物#</a>, objectTitle=ASCO2013：新免疫治疗药物对多种肿瘤具有活性, objectType=article, longId=21613, objectId=9c0f216136c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c0f216136c, replyNumber=0, likeNumber=70, createdTime=2014-01-29, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c0f216136c, moduleTitle=ASCO2013：新免疫治疗药物对多种肿瘤具有活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c0f216136c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

免疫治疗药物

2020-05-29

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#免疫治疗药物#

肺癌，靶向及免疫治疗药物汇总表（2022年6月）

2022-09-06

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#免疫治疗药物#

Aimmune Therapeutics在EAACI PAAM数字会议上呈报长期每日口服免疫治疗药物PALFORZIA®（花生过敏原粉剂-dnfp）的免疫学结果新数据

2022-09-20

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#免疫治疗药物#

肺癌，靶向及免疫治疗药物汇总表(2022年1月)

2022-04-26

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#免疫治疗药物#

PD-1免疫治疗药物拓益®尿路上皮癌适应症在中国获批

2021-11-30

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#免疫治疗药物#

Personalis, Inc.新发表的数据显示，新型复合生物标志物NEOPS™可用于预测晚期黑色素瘤患者对癌症免疫治疗药物的应答

2022-06-22

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#免疫治疗药物#

国内结直肠癌一线免疫治疗药物获批，国内PD-1竞争加剧

2022-01-20

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#免疫治疗药物#

五类新型肿瘤免疫治疗药物，加强版PD-1药物即将到来

2021-03-31

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#免疫治疗药物#

过敏性疾病取得里程碑进展，全球蒿属花粉舌下免疫治疗药物上市

2022-03-11

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#免疫治疗药物#

CSCO 2020丨CDE高级审评员夏琳：肿瘤免疫治疗药物的临床研发和审评考虑

2021-04-11

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#免疫治疗药物#

中国胃癌免疫治疗药物欧狄沃®获批，生存期显著延长

2021-02-11

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#免疫治疗药物#

针对广泛期小细胞肺癌，免疫治疗药物Imfinzi显著改善生存获益和持久疗效

2020-07-01

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#免疫治疗药物#

2018年值得关注的肿瘤免疫治疗药物

2018-08-26

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#免疫治疗药物#

ANN ONCOL:肿瘤类型和免疫治疗药物类别的不同对免疫治疗不良事件的发生差异如何？

2018-06-17

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#免疫治疗药物#

PNAS:KWAR23抗体——肿瘤免疫治疗药物的有力助手

2018-09-25

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#免疫治疗药物#

Lancet Oncol：PD-1免疫治疗药物能有效治疗恶性胸膜间皮瘤 (KEYNOTE-028)

2017-11-13

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#免疫治疗药物#

强大的肠道菌群！竟然影响黑色素瘤病人对免疫治疗药物的应答

2017-08-22

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#免疫治疗药物#

PD-L1免疫治疗药物avelumab牵手表观药物entinostat，联合治疗卵巢癌研究启动

2016-04-27

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#免疫治疗药物#

BMS、默沙东及罗氏免疫治疗药物将成为ASCO会议的焦点

2014-09-24

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#免疫治疗药物#

2013年回顾：癌症免疫治疗药物加速崛起

2014-06-28

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#免疫治疗药物#

ASCO2013：新免疫治疗药物对多种肿瘤具有活性

2014-01-29

科室
- - 订阅+
  - 更多科室
工具
服务